摘要：Correction to:
Scientific Reports 10.1038/s41598-021-91589-2, published online 08 June 2021
The original version of this Article contained errors in the horizontal axis label of Figure 3. As a result,
"6 months, 9 months, and 12 months"
now reads:
"12 months, 24 months, and 36 months".
The original Figure
3 and accompanying legend appear below.
Figure 3
Changes in mean central foveal thickness during the 36-month anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization (PCV/AT1), and typical neovascular age-related macular degeneration (nAMD). The mean central foveal thickness showed a significant decrease when comparing from baseline through the 36 months follow-up for the groups. However, there was no significant difference between the groups in central foveal thickness at 3, 12, 24, and 36 months.
The original Article has been corrected.
